Predictive value of KRAS mutations in chemoresistant CRC

被引：30

作者：

Lievre, Astrid ^{[2
]}

Laurent-Puig, Pierre ^{[1
]}

机构：

[1] Univ Paris 05, Sch Med, F-75006 Paris, France

[2] INSERM Lab, Paris, France

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 06期

关键词：

METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; CETUXIMAB; PANITUMUMAB;

D O I：

10.1038/nrclinonc.2009.69

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

引用

页码：306 / 307

页数：3

共 50 条

[31] Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, Tomoya
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 163 - 171
[32] Kras Mutations and Egfr Expression as Prognostic and Predictive Factors in Cancer Patients
Hussein, Alaa Ramthan
Dawood, Wedad Salih
JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2023, 30 (03): : E393 - E403
[33] Kras Mutations and Egfr Expression as Prognostic and Predictive Factors in Cancer Patients
Hussein, Alaa Ramthan
Dawood, Wedad Salih
JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2023, 30 (03): : E393 - E403
[34] Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
Qiu, Li-Xin
Mao, Chen
Zhang, Jian
Zhu, Xiao-Dong
Liao, Ru-Yan
Xue, Kai
Li, Jin
Chen, Qing
EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2781 - 2787
[35] Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
Mellema, Wouter W.
Dingemans, Anne-Marie C.
Smit, Egbert F.
Derks, Jules
Heideman, Danielle A. M.
van Suylen, Robertjan
Thunnissen, Frederik B.
CLINICAL CANCER RESEARCH, 2012, 18 (03)
[36] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
Dingemans, Anne-Marie
Smit, Egbert F.
Heideman, Danielle
Mellema, Wouter
Derks, Jules
Van, Robertjan Suylen
Thunnissen, Erik
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
[37] Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC).
Blagoev, Krastan B.
Pichun, Mauricio Emmanuel Burotto
Wilkerson, Julia
Blanco-Codesido, Montserrat
Dominguez, Edward Espinal
Garcia-Altonso, Pilar
Fojo, Antonio Tito
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer
Kadowaki, Shigenori
Kakuta, Miho
Takahashi, Shuhei
Takahashi, Akemi
Arai, Yoshiko
Nishimura, Yoji
Yatsuoka, Toshimasa
Ooki, Akira
Yamaguchi, Kensei
Matsuo, Keitaro
Muro, Kei
Akagi, Kiwamu
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (04) : 1275 - 1283
[39] Origin and prognostic value of circulating KRAS mutations in lung cancer patients
Gautschi, O.
Huegli, B.
Ziegler, A.
Gugger, M.
Heighway, J.
Ratschiller, D.
Mack, P. C.
Gumerlock, P. H.
Kung, H. J.
Stahel, R. A.
Gandara, D. R.
Betticher, D. C.
CANCER LETTERS, 2007, 254 (02) : 265 - 273
[40] Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer
Wang, Yuanyuan
Zhao, Zhi
Zhuang, Jing
Wu, Xinxin
Wang, Zhizhong
Zhang, Bing
Gao, Ge
Zhang, Yinping
Guo, Caili
Xia, Qingxin
JOURNAL OF CANCER, 2021, 12 (12): : 3515 - 3528

← 1 2 3 4 5 →